Tobe, K., Suganami, H., & Kaku, K. (2017). Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline. J Diabetes Investig.
Citação norma ChicagoTobe, Kazuyuki, Hideki Suganami, and Kohei Kaku. "Sodium–glucose Cotransporter 2 Inhibitor, Tofogliflozin, Shows Better Improvements of Blood Glucose and Insulin Secretion in Patients With High Insulin Levels At Baseline." J Diabetes Investig 2017.
Citação norma MLATobe, Kazuyuki, Hideki Suganami, and Kohei Kaku. "Sodium–glucose Cotransporter 2 Inhibitor, Tofogliflozin, Shows Better Improvements of Blood Glucose and Insulin Secretion in Patients With High Insulin Levels At Baseline." J Diabetes Investig 2017.